Mesenchymal Cell News Volume 8.20 | May 24 2016

Mesenchymal Stem Cells Are Sensitive to Bleomycin Treatment
Scientists demonstrated that human bone marrow-derived mesenchymal stem cells (MSCs) are relatively sensitive to bleomycin exposure compared to adult fibroblasts. MSCs revealed increased levels of apoptosis after bleomycin treatment, while cellular morphology, stem cell surface marker expression and the ability for adhesion and migration remained unchanged. [Sci Rep] Full Article

Galectin-3 Enhances Migration of Miniature Pig Bone Marrow Mesenchymal Stem Cells through Inhibition of RhoA-GTP Activity
The authors assessed whether galectin-3 (Gal-3) increases the migration of miniature pig bone marrow mesenchymal stem cells (BM-MSCs). Gal-3 was knocked down by short hairpin RNA or overexpressed using a lentiviral vector in Wuzhishan miniature pig BM-MSCs. [Sci Rep] Full Article

Clinical-Scale Expansion of Mesenchymal Stromal Cells: A Large Banking Experience
Researchers describe the constitution of an allogeneic human third-party mesenchymal stromal cell bank from screened healthy volunteer donors in compliance with quality specifications and ISCT-release criteria and report follow-up of different aspects of this activity since 2007. [J Transl Med] Full Article

Estrogen Receptor α and β in Mouse: Adipose-Derived Stem Cell Proliferation, Migration, and Brown Adipogenesis In Vitro
The authors investigated effects of estrogen receptor (ER)α and ERβ on adipose-derived stem cells proliferation, migration, as well as in adipogenesis. [Cell Physiol Biochem] Full Article

Zoledronic Acid In Vivo Increases In Vitro Proliferation of Rat Mesenchymal Stromal Cells
Investigators evaluated the effect of in vivo zoledronic acid (ZA) treatment and possible concomitant effects of ZA and fracture on the ex vivo osteogenic capacity of rat mesenchymal stromal cells. [Acta Orthop] Abstract

Accumulation of Apoptosis-Insensitive Human Bone Marrow-Mesenchymal Stromal Cells after Long-Term Expansion
Scientists investigated whether long-term-cultured human bone marrow mesenchymal stromal cells (MSCs) are insensitive to apoptotic stimulation. To examine this, they established replicative senescent cells from long-term cultures of human bone marrow MSCs. [Cell Biochem Funct] Abstract

IN VIVO

Successful In Vivo MRI Tracking of MSCs Labelled with Gadoteridol in a Spinal Cord Injury Experimental Model
Murine mesenchymal stem cells (MSCs) labeled with the clinically approved MRI agent Gadoteridol through a procedure based on the hypo-osmotic shock were successfully tracked in vivo in a murine model of spinal cord injury. [Exp Neurol] Abstract

vIL-10-Overexpressing Human MSCs Modulate Naïve and Activated T Lymphocytes following Induction of Collagenase-Induced Osteoarthritis
Researchers sought to establish the in vivo immune response in collagenase-induced osteoarthritis and investigate the ability of human mesenchymal stem cells (MSCs) overexpressing viral interleukin 10 (vIL-10) to modulate immune populations and delay/prevent disease progression. [Stem Cell Res Ther] Full Article

Transplantation of Human Adipose Mesenchymal Stem Cells in Non-Immunosuppressed GRMD Dogs Is a Safe Procedure
Xenogeneic cell transplantation, which was done without immunosuppression, was well tolerated in all animals with no apparent long-term adverse effect. Scientists showed that repeated heterologous stem-cell injection is a safe procedure, which is fundamental before starting human clinical trials. [Stem Cell Rev] Abstract

The Clinical Application of Mesenchymal Stromal Cells in Hematopoietic Stem Cell Transplantation
The authors outline the progress of mesenchymal stromal cells in preventing and treating engraftment failure, graft-versus-host disease following hematopoietic stem cell transplantation and critically discuss unsolved issues in clinical applications. [J Hematol Oncol] Full Article

Visit our reviews page to see a complete list of reviews in the mesenchymal cell research field.

Bone Therapeutics to Enhance Value of Its Severe Osteoporosis Program by Transitioning to Allogeneic Development
Bone Therapeutics announced that it plans to commence a Phase II trial for the treatment of severe osteoporosis with its allogeneic “off the shelf” bone cell therapy product, ALLOB^®. [Bone Therapeutics S.A.] Press Release

From our sponsor: Learn about detecting cancer stem cells with ALDEFLUOR™. Watch the webinar.

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the mesenchymal cell community.

NEW Postdoctoral Positions – Regenerative Medicine (Gladstone Institutes)

Scientific Communications and Publishing Coordinator (STEMCELL Technologies Inc.)

Research Technologist – Mesenchymal Stem Cell Biology (STEMCELL Technologies Inc.)

Professor – Hematology and Cell Therapy (Karolinska Institutet)

Postdoctoral Position – Bone/Stem Cell Biology (University of California, Los Angeles)

Postdoctoral Fellow – Skeletal Biology (Perelman School of Medicine)

Postdoctoral Scholar – Neurobiology (Penn State College of Medicine)

Postdoctoral Fellow – Tissue Regeneration (University of Pennsylvania)

Postdoctoral Researcher – Stem Cell Biology, Regenerative Medicine (NUI Galway)

PhD Student Position – Bone Biology (KU Leuven)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.